- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.04. | bioAffinity Technologies files to sell 1.63M shares for holders | 1 | Seeking Alpha | ||
| 04.04. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 01.04. | bioAffinity Technologies, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 01.04. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.04. | bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results | 136 | Business Wire | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer... ► Artikel lesen | |
| 13.03. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | bioAffinity Technologies secures $2.5 million in stock sale | 2 | Investing.com | ||
| 06.03. | BioAffinity Technologies to raise $2.5M from stock offering and private placement | 2 | Seeking Alpha | ||
| 05.03. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | bioAffinity reports surge in early-stage lung cancer test orders | 1 | Investing.com | ||
| 31.01. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.01. | bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money Show on Bloomberg TV | 586 | ACCESSWIRE | ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money®... ► Artikel lesen | |
| 30.11.23 | bioAffinity Technologies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.11.23 | bioAffinity Technologies files for a $25M mixed shelf offering | 2 | Seeking Alpha | ||
| 15.11.23 | bioAffinity Technologies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.11.23 | bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update | 133 | Business Wire | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases... ► Artikel lesen | |
| 14.11.23 | bioAffinity Technologies, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08.23 | bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update | 216 | Business Wire | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases... ► Artikel lesen | |
| 15.05.23 | bioAffinity Technologies Reports First Quarter 2023 Financial Results | 248 | Business Wire | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,540 | -2,53 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,866 | +6,13 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,842 | 0,00 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 21,740 | +2,45 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,340 | 0,00 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| ONCOLYTICS BIOTECH | 1,030 | 0,00 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,900 | +9,11 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,914 | 0,00 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 9,320 | +6,15 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 14,975 | +1,59 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 8,750 | 0,00 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,990 | -0,33 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,330 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,670 | -5,65 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 11,570 | +7,73 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen BIOAFFINITY TECHNOLOGIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
